IMMUNEONCO-B (01541) announced that the first patient in the Phase 1 clinical trial of IMC-003/IMM72 has been successfully dosed, marking a significant milestone in the group's clinical research of IMC-003/IMM72 and establishing a solid foundation for subsequent clinical trials.
IMC-003/IMM72 is a genetically modified next-generation activin receptor IIA-Fc (ActRIIA-Fc) fusion protein with enhanced activity and quality. The group holds global intellectual property rights as well as development and commercialization rights for IMC-003/IMM72.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。